Recruiting
Phase 1

VET3-TGI

Sponsor:

KaliVir Immunotherapeutics

Code:

NCT06444815

Conditions

Solid Tumor, Adult

Microsatellite Stable Colorectal Cancer

Head and Neck Squamous Cell Carcinoma

Cervical Cancer

Kidney Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

VET3-TGI

Pembrolizumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-01. This information was provided to ClinicalTrials.gov by KaliVir Immunotherapeutics on 2025-04-10.